3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
3
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
1
Neoplasms
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Adenocarcinoma
1
Interventions
Gemcitabine
35
Cisplatin
21
Capecitabine
17
Oxaliplatin
16
Leucovorin
11
Fluorouracil
11
pembrolizumab
8
S 1 (combination)
8
Nivolumab
6
tremelimumab
5
durvalumab
5
Bevacizumab
5
lenvatinib
4
Irinotecan
4
trametinib
3
titanium silicide
3
atezolizumab
3
Radiofrequency Ablation
3
zanidatamab
2
vandetanib
2
irinotecan sucrosofate
2
derazantinib
2
camrelizumab
2
binimetinib
2
apatinib
2
Trastuzumab
2
Tegafur
2
Radiotherapy
2
Panitumumab
2
Ipilimumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Biliary Tract Neoplasms
×
gemcitabine-oxaliplatin regimen
×
Clear all
NCT01267344
2016-05-04
BTC
National Health Research Institutes, Taiwan
Phase 2
Completed
122 enrolled